Can a phone app help kids move better? school trial aims to find out
NCT ID NCT07679633
First seen Jul 01, 2026 · Last updated Aug 13, 2026 · Updated 4 times
Summary
This study tests whether a mobile app called Geego Kids can improve motor skills in first-grade children. Over 12 weeks, teachers lead short movement breaks in class, and children do weekly homework activities with family support. The goal is to see if the app helps kids become more physically active and confident in their movement abilities compared to standard school routines.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Geego Kids mobile app
- What this could lead to
- If effective, this app could help schools easily integrate motor skill development into daily routines, potentially improving children's physical health and confidence.
- What could go wrong
- This is a relatively small, early-stage study in healthy children, so results may not apply broadly. The app's success depends on consistent use by teachers and families.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tampere University
Tampere, Finland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test